The activation of the renin angiotensin aldosteron (RAA) system plays a major role in the progression of chronic kidney disease (CKD). Inhibition of the RAA system ameliorates renal injury and improves the prognosis of CKD patients (1-3). On the basis of solid evidence from numerous animal model experiments and clinical trials of
The activation of the renin angiotensin aldosteron (RAA) system plays a major role in the progression of chronic kidney disease (CKD) . Inhibition of the RAA system ameliorates renal injury and improves the prognosis of CKD patients (1) (2) (3) 
the AT2 receptor is induced by tissue injury although it is not down-regulated by high angiotensin II. The function of AT2 receptor is less clear but it has been shown that activation of AT2 receptor potentially has both protective and adverse effects on the kidney. AT2 receptor protects the kidney against ischemic injury and stimulates proinflammatory pathway by induction of NF-kB (3).
The clinical trials to compare the effects of ACEI and ARB are listed in Table 1 193-198, 2006. 
